Back to discover
Disease
Paresthesia
Late-stage therapeutic developmentEmerging researchRising momentum
3
Publications
8
Clinical trials
1
Related conditions
2019
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2019-08-16The Lancet. Oncology
Research2016-11-01Neurosurgery
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q4 2029.
Upcoming Milestones
- Q4 2029Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)
- Q4 2029Evaluation of the Gut Microbiome Profiles in Patients With Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial With Ozone OzoParQT (NCT06706544).
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20292026-09-25
Upcoming trial readoutHigh impact
Results expected Q4 20292026-09-18
Clinical MilestonesViewHide
Results expected
- 2026-09-25Evaluation of the Gut Microbiome Profiles in Patients With Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial With Ozone OzoParQT (NCT06706544).Results expected Q4 2029
- 2026-09-18Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)Results expected Q4 2029
Activity timeline2
- 2026-09-25ClinicalEvaluation of the Gut Microbiome Profiles in Patients With Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial With Ozone OzoParQT (NCT06706544).Results expected Q4 2029
- 2026-09-18ClinicalEffectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)Results expected Q4 2029
Clinical trials
The current development programme across all trial phases.
Clinical programme
8
3
6
4
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
Most influential
Recent publications
Leading journals3
- Blood1
- Neurosurgery1
- The Lancet. Oncology1
Leading researchers8
- Amin A1
- Amirdelfan K1
- Arén Frontera O1
- Barthélémy P1
- Benyamin R1
- Beuselinck B1
- Bracarda S1
- Bundschu R1
Affiliations (unnormalised)6
- *Center for Clinical Research and Carolina's Pain Institute1
- Aarhus University Hospital1
- Barts Cancer Institute1
- Beth Israel Deaconess Medical Center1
- Cleveland Clinic Taussig Cancer Institute1
- Dana-Farber Cancer Institute1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Subjective cutaneous sensations (e.g., cold, warmth, tingling, pressure, etc.) that are experienced spontaneously in the absence of stimulation.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.